NCT05108935View on ClinicalTrials.gov

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Opioid UseOpioid Use DisorderRisk ReductionHivHepatitis C
Interventions
DRUG

Suboxone

Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.

DRUG

Truvada

Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.

DRUG

Mavyret

Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.

Trial Locations (2)

27403

NC Survivors Union, Greensboro

27701

Duke Department of Population Health Sciences, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Center for AIDS Research (CFAR)

UNKNOWN

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Duke University

OTHER